Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995273 | 0.91 | MET (0.41) | METGABRA1TMEM97MAP2K4NR3C2 | |
| SCHEMBL9906866 | 0.86 | GABRA1 (0.41) | METGABRA1TMEM97MAP2K4NR3C2 | |
| SCHEMBL4985352 | 0.80 | GABRA1 (0.48) | METGABRA1TMEM97MAP2K4NR3C2 | |
| SCHEMBL9906872 | 0.79 | GABRA1 (0.41) | METGABRA1TMEM97MAP2K4NR3C2 | |
| SCHEMBL27780474 | 0.77 | GABRA1 (0.36) | METGABRA1TMEM97MAP2K4NR3C2 | |
| SCHEMBL9906879 | 0.76 | GABRA1 (0.43) | METGABRA1TMEM97MAP2K4NR3C2 | |
| SCHEMBL9906881 | 0.75 | GABRA1 (0.42) | METGABRA1TMEM97NR3C2 | |
| SCHEMBL9906878 | 0.73 | GABRA1 (0.40) | METGABRA1TMEM97NR3C2 | |
| SCHEMBL4781102 | 0.73 | GABRA1 (0.41) | GABRA1MAP2K4 | |
| SCHEMBL9906886 | 0.72 | GABRA1 (0.42) | METGABRA1TMEM97NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | MET 1/4885GABRA1 2962/4885TMEM97 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.